The efficacy of the treatment of advanced gastric cancer is not very good. The response rate to the original etoposide-leucovorin-5-fluorouracil (ELF) treatment is 53% with tolerable side effects. Whetherincreasing the doseintensity by prolonging the duration of infusion with 5-fluorouracil (5-FU) and leucovorin (LV) from 3 to 5 days for advanced or metastatic gastric cancer patients would enhance the efficacy but not increase side effects is still unknown. Methods: Thirty-six advanced or metastatic gastriccancerandchemotherapy-na'lve patients with measurable or evaluable diseases were scheduled to receive intravenous etoposide 100 mg/m 2/day on days2-4, LV300 mg/m 2/day intravenously and5-FU500 mg/m 2/day intravenously on days 1-5, every 4 weeks. All patients who received at leasttwo courses of chemotherapy were evaluated for tumor response, survival and response duration and toxicity according to the WHO criteria. Results: Thirteen patients showed a response, including five with complete response (CR). The overallresponse ratewas 36% (95% confidence interval, CI,20-52%) inthewholegroupand46% (95% CI 28-66%) in the 28 patients with measurable disease. The median progression-free interval and overall median survival time were 5 and 7 months, respectively. The most frequent toxicity was alopecia (grade III/ 56.3%). The incidence of grade III or greater myelosuppression was 5.9%. No treatment-related death occurred.
INTRODUCTION
The prognosis of gastric cancer has remained unchanged in the past decade. It frequently presents with disseminated disease. The 5-year survival rate remains less than 20% and the median survival duration of patients with untreated metastatic carcinoma ranges between 3 and 6 months (1). Gastric cancer is a relatively chemosensitive malignancy, a number of drugs have been studied and several antineoplastic regimens have demonstrated a modest degree of activity (2, 3) . Although the older regimens, such as FAM (5-fluorouracil, adriamycin, mitomycin C) and the secondgeneration protocols, including EAP (etoposide, doxorubicin, cisplatin) are effective in the treatment of advanced gastric cancer, the intensity of their adverse effects precludes popular usage and allows a low toxicity regimen, such as the ELF (etoposide, leucovorin, 5-fluorouracil) regimen, to provide acceptable palliation in the clinical oncology field (4) (5) (6) (7) (8) . The original response rate of the ELF regimen was 53%, including 12% complete response and 11.0 months median survival duration with acceptable toxicity (8) . Many subsequent studies using the ELF regimens had shown comparable results (9, 10) .
In a previous pilot study of the efficacy and toxicity of a mild modification of ELF by increasing the total dosage of 5-fluorouracil (PU) to 400 mg/m 2jday and leucovorin (LV) to 200 mg/m 2jday for 5 days in 10 Chinese gastric cancer patients, we found a response rate of about 40%, with generally mild myelosuppression and gastrointestinal side effects (11) . In order to see whether a higher infusion dosage of 5-FU and LV would improve the response rate and survival status with comparative toxicity, we further increased the dosages of 5-FU and LV to treat our patients with advanced gastric cancer. This paper presents our data on the efficacy and toxicity of the modified ELF regimen.
PATIENTS AND METHODS
From May 1993 to December 1995, 36 patients with advanced gastric cancer were entered into this study. Eligibility criteria included histological confirmation of adenocarcinoma of the stomach or gastroesophageal junction and an assessment of advanced or metastatic disease.The definitionof measurable disease was a known tumor mass that could be clearly measured in two dimensions on physical examination or image studies, preferably by CT scan or ultrasound. Evaluable disease refers to gastric cancer that includes peritoneal carcinomatosis and ascites which could not be measured in a conventional fashion. Metastatic disease was defmed as either liver involvement, extra-abdominal metastasis or peritoneal seeding with or without ascites formation. There were 14 patients with either local recurrence or metastasis after surgical resection for their primary tumor and 22 patients with advanced or metastatic disease in unresectable status. A WHO performance status of Q and a life expectancy of at least 6 weeks were required. Patients who had received prior chemotherapy or radiation therapy were not admitted to the study. Patients were required to have an adequate hematological (WBC count~4000/Jll, platelet count~100 OOO/Jll), hepatic (total bilirubinsz.O mg/dl) and renal function (serum creatinine levels l.S mg/dl). No patients with clinical evidence of central nervous system (CNS) metastases prior to chemotherapy or second malignancy were enrolled. All patients had to have measurable or assessable tumors. Staging procedures included an endoscopy, abdominal computed tomography (Cf) scan, abdominal ultrasonography, chest X-ray and whole body bone scan. To evaluate the response after chemotherapy, the same diagnostic procedures were used. Blood counts were checked weekly. Evaluation of liver and renal function and of measurable disease was performed prior to each chemotherapy course and 4 weeks after the last course. Follow-up examinations were done monthly.
The criteria for response were defmed as usual (4, 5) . Briefly, a complete response (CR) required complete resolution of all known disease, determined by two observations not less than 4 weeks apart for patients with measurable disease and complete disappearance of all known disease for at least 4 weeks for patients with evaluable disease. Partial response (PR) was defmed as >50% reduction in the sum of the products of the perpendicular diameter of all measured lesions or >50% lesion decrease agreed upon by two observers for a minimum of 4 weeks. Stable disease (SD) was defmed as <50% decrease or <25% increase in the size of measurable lesions and progressive disease (PD) as~25% increase in tumor burden or the appearance of new lesions. The patients with peritoneal carcinomatosis or ascites were difficult to evaluate by either physical examination or conventional image studies; the best therapeutic response in those patients was recorded as stable disease (if they remained in the study for longer than 12 weeks). The achievement of CR or PR required the absence of any significant loss of body weight (>10%) or deterioration of symptoms or performance status (>1, WHO).
Patients started to receive treatment after a full explanation of the purpose, procedures and risks of the study and signed a statement of informed consent approved by the Hospital Ethics Committee. The chemotherapy consisted of LV 300 m~m2/day given as a 30 min intravenous infusion, followed immediately by a 1 h 5-FU 500 m~m2/day infusion for fIve consecutive days and etoposide 100 m~m2/day intravenous infusion for 1 h on days 2-4. The dose of 5-FU was reduced by 10% after the occurrence of grade II or higher mucositis or diarrhea, grade IV leucopenia or grade ill or higher ill thrombocytopenia. Courses were repeated every 28 days. If complete response was achieved, continued chemotherapy was given for 12 months in total or until disease progression. Patients with PR/SD received chemotherapy until progression.
All patients who received at least two courses of chemotherapy were evaluated for tumor response, survival and response duration and toxicity according to the WHO criteria (12) . The 95% exact confidence interval (CI) for response was also calculated. Survival was calculated for all patients entering the study and defmed as the period encompassing from the first day of treatment to death. Survival and time to progression were analyzed by the KaplanMeir method (13) . The therapeutic response was compared between older and younger than 65 years or with and without primary tumor by the chi-squared analysis of contingency test.
RESULTS
Thirty-six patients (31 male and five female) entered the study, all of whom were evaluable for response and toxicity assessment. The patients' characteristics are shown in Table 1 . The median age was 66 years (range 30-79 years). All patients were of advanced status, including 15 with liver involvement and intra-abdominal lymphadenopathy, seven with peritoneal carcinomatosis, three with intra-abdominal lymphadenopathy and pancreatic head involvement causing obstructive jaundice, eight with disseminated intra-abdominal lymphadenopathy, two with lung metastasis and one with supraclavicular fossa lymph node metastasis. There were 28 patients with measurable disease and eight patients in the evaluable group. A total of 153 courses of chemotherapy (mean 4.2 courses per patient, range 2-12) were administered.
The treatment results in 28 patients with measurable disease are shown in Table 2 . Thirteen patients had tumor responses, including five patients with a complete response. Eight patients had stable disease. The overall response rate (CR/PR) in the whole group was 36% (95% confidence interval, CI, 20-52%). The response rate (CR/PR) in the patients with measurable lesions was 46% (95% CI 28-66%). No patients underwent exploratory laparotomy. An analysis of response by tumor status revealed a low response rate (38%, 95% CI 14-61 %) in patients with primary tumor. In patients without primary tumor, the response rate was 58% (95% CI 30-86%). The response rate was significantly related between the patients with and without primary tumor (p = 0.012, chi squared test). There was no significant difference in the response rates for the older and younger «65 years) patients (p = 0.914, chi squared test). The overall median survival time was 7 months (range 1.5-19 months). The toxicities are shown in Table 3 . Myelosuppression was usually mild. Leucopenia and thrombocytopenia of WHO grade III/IV occurred in nine (5.9%) and one (0.7%) of the chemotherapy courses, respectively. Episodes of fever associated with severe granulocytopenia occurred in two patients. Grade 1/11 nausea/vomiting occurred in 22 (14.4%) courses of chemotherapy. Patients exhibited chemotherapy-induced grade 1/11 diarrhea in 35 (22.8%) courses. One chemotherapy course was delayed for 2 weeks and two treatment schedules were deferred for 1 week owing to grade IV leucopenia. The most frequent toxicity was grade lIII hair loss in 86 (56.3%) courses of chemotherapy. About 11 (7.2%) courses of chemotherapy developed grade 1/11 hepatotoxicity after scheduled therapy. No patient died of therapy-related complications. jday to treat 24 advanced gastric adenocarcinoma patients, resulting in a 21% response rate with 7 months median survival. Our study, lengthening the infusion duration of 5-FU and LV from 3 to 5 days, with an etoposide dose of 100 mg/m 2 jday for 3 days, demonstrated a 46% response rate in patients with measurable lesions, including five patients in CR and a median survival duration of 7 months. There was no age-related difference in response rate. With regard to the primary tumor, there was statistical difference in response rate of patients with and without it (38 vs 58%, p < 0.05). If the patient's primary tumor had not been removed, it meant that the patient's disease was unresectable or of a more advanced status. Most of our patients with advanced gastric cancer without primary tumor belonged to the group with recurrence or metastases after prior radical resection or palliative gastrectomy. From the viewpoint of clinical oncology, bulky tumor mass is a poor prognostic sign, contributing to the fact that patients with primary tumor have an inferior therapeutic result compared with those without primary tumor. Compared with our previous data, further increasing the infusion dosage of 5-FU and LV does not enhance the response rate (40 vs 36%) and prolong the survival duration (10) . Increasing the dose of 5-FU from 5 to 8 g/m 2 in 1 g/m 2 increments in each course until toxic effects led to a very small increment (4%) in objective responses, but resulted in severe toxicities, including CNS, stomatitis, hematological, gastrointestinal systems and sepsis (16) . Whether increasing the infusion duration and dosages of 5-FU and LV advanced gastric cancer can affect the response rate and survival duration is still questionable. In our study, no mortality could be attributed to treatment and patients tolerated the drug very well. Geffen et al. (17) used the original ELF regimen, demonstrated a~grade III hematological toxicity in 11/63 (17%) cycles of chemotherapy. Our results showed 3.9% grade III and 2% grade IV leucopenia. This is lower than that of the original ELF regimen (grade III/IV leucopenia, 16/4%). The grade 1/11 (56.3%) and no grade III/IV alopecia in our study was also lower than that reported by Wilke et al. (63 and 30% of grade 1/11 and III alopecia, respectively). The occurrence of nausea/vomiting and mucositis/ stomatitis after chemotherapy was also mild in our patients. It seems that our patients can tolerate a high dose intensity of 5-FU and LV better than in other series. Whether this is due to racial differences needs further study.
The goal in the treatment of advanced gastric cancer is not only to improve the response rate but also to sustain a longer survival. Although the response rates of advanced gastric cancer in earlier reports with EAP and FAMTX were better than those with the other regimens, the 1 year survival rate was only 17% for FAMTX and 7% for EAP. Less than 5% of patients could survive more than 2 years (18) (19) (20) . The overall median survival in our study was 7 months and no patient survived more than 19 months. This is consistent with the survival data with the original ELF, FAMTX and EAP treatments (7, 8, (17) (18) (19) (20) (21) . The reasons why none of our patients survived more than 19 months might have been due to lack of inclusion of other combined-modality treatments or to relatively advanced disease status. The possible benefit of radiation therapy in addition to chemotherapy in the treatment of locally advanced gastric cancers was reported with a 17% 5-year survival rate (22) . It has been assumed that in locally advanced tumor stages, even after induction of pathological CR (pCR), microscopic foci of probably chemotherapy-resistant tumor cells might exist and need to be aggressively eradicated by other combined modality therapies (23) . The inclusion of either surgical resection or radiation in combined-modality treatment might be a reasonable approach to controlling the residual tumor foci (6) . Unfortunately, none of our patients received either treatment after clinical response owing to their resistance/refusal to receive more aggressive therapy or poor general conditions. The advanced, metastatic status of our patients might also partially explain the relatively short survival.
In conclusion, our modified ELF regimen can be safely administered to advanced gastric cancer patients. The 46% overall response rate in patients with measurable disease and 7 months median survival time with good tolerability are not superior to the results of the original ELF regimen or our previous data. Further escalating the dose intensity of the original ELF may not be useful in the treatment of patients with advanced gastric cancer. Studies focusing on more innovative protocols may be tried in exploring the efficacy of chemotherapy on patients with advanced gastric cancer. The response rate of advanced gastric cancer is dependent on whether the primary tumor exists or not.
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